Innova Captab Limited IPO
₹426 - ₹448
33
55.26
| Open Date: | 21-Dec-2023 |
| Close Date: | 26-Dec-2023 |
| Allotment Date: | 27-Dec-2023 |
| Listing Date: | 29-Dec-2023 |
| Listing Price: | ₹526.85/- |
| Face Value: | ₹10 Per Equity Share |
| Issue Price: | ₹426-448 Per Equity Share |
| Issue Size: | Total Issue Size [.] shares (aggregating up to ₹570.00 Cr) : Fresh Issue [.] shares (aggregating up to ₹320.00 Cr) : Offer for Sale 5,580,357 shares of ₹10 (aggregating up to ₹250.00 Cr) |
| Market Lot (Min Amount): | Retail - ₹14,784 : S-HNI - ₹206,976 : B-HNI - ₹1,005,312 |
As on | QIB | Nll | Rll | Total |
|---|---|---|---|---|
| Shares Offered/Reserved | 2,544,643 | 1,908,482 | 4,453,125 | 8,906,250 |
| Day 1 - 21-12-23 05:00 PM | 0.44x | 1.00x | 2.26x | 1.47x |
| Day 2 - 22-12-23 05:00 PM | 1.08x | 3.38x | 5.22x | 3.64x |
| Day 3 - 26-12-23 05:00 PM | 116.73x | 64.95x | 17.15x | 55.26x |
| Total No. of Application: | 2,392,538 (Approx.) | |||
| Retail Subscription on the basis of Apps: | 17.73x | |||
| Earning Per Share(EPS) | ₹14.16/- |
| P/E Ratio | 31.64 |
| RoNW | 24.58% |
| Net Asset Value (NAV) - Post Issue: | ₹57.60/- |
| Total Assets | Total Revenue | Profit After Tax | |
|---|---|---|---|
| 31 Jun,2023 | 1,086.16 | 234.37 | 17.59 |
| 31 Mar,2023 | 704.41 | 935.58 | 67.95 |
| 31 Mar,2022 | 575.48 | 803.41 | 63.95 |
| 31 Mar,2021 | 369.62 | 412.03 | 34.50 |
| Pre Issue Share Holding | 66.85% |
| Post Issue Share Holding | N/A% |
| 1. Namely Manoj Kumar Lohariwala |
| 2. Vinay Kumar Lohariwala |
The Company proposes to utilise the Net Proceeds from the Fresh Issue towards funding the following objects:
- Repayment and / or prepayment in part or in full, of certain outstanding loans of the Company;
- Investment in the Subsidiary, UML, for repayment and / or prepayment in part or full of outstanding loans availed by UML;
- Funding the working capital requirements; and
- General corporate purposes
Incorporated in January 2005, Innova Captab Limited is a pharmaceutical company operating in three business segments. Firstly, it provides contract development and manufacturing services to Indian pharmaceutical companies. Secondly, the company has a domestic business dealing in branded generics. And thirdly, the company has an international business that deals in branded generics.
The company's product portfolio includes tablets, capsules, dry syrups, dry powder injections, ointments and liquid medicines.
In the financial year 2023 and the three months ended June 30, 2023, the company produced and sold more than 600 different types of generics. These products were distributed under the company's own brands in the Indian market through a network of approximately 5,000 distributors and stockists and over 150,000 retail pharmacies. In addition, Innova Capitab exported its branded generic products to 20 and 16 countries in FY2023 and the three months ended June 30, 2023, respectively.
As of October 31, 2023, the company employed a team of 29 scientists and engineers in its research and development laboratory. The company's manufacturing facility is located in Buddi, Haryana
The company's customer base includes Cipla, Glenmark Pharmaceuticals, Wockhardt, Corona Remedies, Emcure Pharmaceuticals, Lupin, Medley Pharmaceuticals, Eris Healthcare, Zuventus Healthcare, Ajanta Pharma, Mankind Pharma, and others.
As of October 31, 2023, the company has 200 active product registrations and 20 registrations pending renewal with international authorities. In addition, 218 new registration applications are being processed with international authorities.
No financial information whatsoever published anywhere, within this application, should be considered as an advise to buy or sell securities or invest in IPOs, or as guide to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
Also we are not a SEBi registered analyst comapny. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published on this application. Above information is based on information available as on date coupled with market perceptions.
If you are agree with app tems and condition to use the app.
Thank you.